A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity
暂无分享,去创建一个
[1] Jean S. Campbell,et al. Liver regeneration. , 2012, Journal of hepatology.
[2] Andreas Plückthun,et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. , 2010, Cancer research.
[3] C. Cavard,et al. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. , 2010, Journal of hepatology.
[4] F. Hagemeister,et al. Denileukin diftitox: a novel immunotoxin , 2009, Expert opinion on biological therapy.
[5] I. Lyakhov,et al. Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors , 2009, Journal of immunotherapy.
[6] A. Plückthun,et al. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins , 2009, Molecular Cancer Therapeutics.
[7] P. Wolf,et al. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. , 2009, International journal of medical microbiology : IJMM.
[8] Brigitte Mack,et al. Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.
[9] H. Fuchs,et al. Targeted tumor therapies at a glance. , 2009, Current drug targets.
[10] B. Boman,et al. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Scheinfeld,et al. VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. , 2008, Current opinion in molecular therapeutics.
[12] Charlotte Kuperwasser,et al. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.
[13] W. Wels,et al. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. , 2007, Cancer letters.
[14] Theresa M. Allen,et al. Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system , 2007, Molecular Cancer Therapeutics.
[15] I. Pastan,et al. Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.
[16] J. Winther,et al. Quantification of protein thiols and dithiols in the picomolar range using sodium borohydride and 4,4'-dithiodipyridine. , 2007, Analytical biochemistry.
[17] I. Pastan,et al. Immunotoxin treatment of cancer. , 2007, Annual review of medicine.
[18] A. Plückthun,et al. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule–targeted liposomal antisense against bcl-2/bcl-xL , 2006, Molecular Cancer Therapeutics.
[19] Andreas Plückthun,et al. Crystal structure of a consensus‐designed ankyrin repeat protein: Implications for stability , 2006, Proteins.
[20] H. Moch,et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. , 2006, Gynecologic oncology.
[21] I. Pastan,et al. Immunotoxins in the treatment of hematologic malignancies. , 2006, Current drug targets.
[22] Takeshi Shimamura,et al. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. , 2006, Neurosurgical focus.
[23] U. Wetterauer,et al. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells , 2006, Cancer Immunology, Immunotherapy.
[24] P. Dalerba,et al. Identification of pancreatic cancer stem cells. , 2006, Cancer research.
[25] A. Plückthun,et al. Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.
[26] W. Wilson,et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Sebastian Harder,et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas , 2005, Breast Cancer Research.
[28] Andreas Plückthun,et al. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.
[29] A. Plückthun,et al. High-affinity binders selected from designed ankyrin repeat protein libraries , 2004, Nature Biotechnology.
[30] N. Van Rooijen,et al. NK Cells, but Not NKT Cells, Are Involved in Pseudomonas aeruginosa Exotoxin A-Induced Hepatotoxicity in Mice1 , 2004, The Journal of Immunology.
[31] Andreas Plückthun,et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.
[32] A. Plückthun,et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] T. Allen. Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.
[34] H. Hollema,et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. , 2001, Cancer research.
[35] A. Plückthun,et al. Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.
[36] Gregor Mikuz,et al. Ep-CAM overexpression in breast cancer as a predictor of survival , 2000, The Lancet.
[37] A. Plückthun,et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. , 1999, Cancer research.
[38] S. Litvinov,et al. The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.
[39] A. Frankel. Immunotoxin therapy of cancer. , 1993, Oncology.
[40] B. Groner,et al. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. , 1992, Cancer research.
[41] I. Pastan,et al. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. , 1991, The Journal of biological chemistry.
[42] R. Collier,et al. Effects of eliminating a disulfide bridge within domain II of Pseudomonas aeruginosa exotoxin A , 1989, Infection and immunity.
[43] Alessandro Lugli,et al. Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.